| abstract |
A polypeptide comprising a first polypeptide and a second polypeptide comprising at least a portion of an immunoglobulin hinge region, comprising one or more cysteine residues, a immunoglobulin CH2 domain and an immunoglobulin CH3 domain, in which i) the first polypeptide comprises mutations I253A, H310A and H435A and the second polypeptide comprises mutations H310A, H433A and Y436A, or ii) the first polypeptide comprises mutations I253A , H310A and H435A and the second polypeptide comprises mutations L251D, L314D and L432D, or iii) the first polypeptide comprises mutations I253A, H310A and H435A and the second polypeptide comprises mutations L251S, L314S and L432S. Pharmaceutical formulation; use. |